# Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

> **NCT01855854** · PHASE2 · COMPLETED · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Esophageal Carcinoma

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT01855854
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-08
- **Final completion:** 2016-01-07
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01855854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01855854, "Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01855854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*